Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

11 citing papers in PubMed.

1. Type 2 diabetes mellitus, antidiabetics, and the risk of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2025
   Article
2. Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.Neurology · 2024
   Observational
3. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly.BMC musculoskeletal disorders · 2020
   Article
4. Nuclear localized C9orf72-associated arginine-containing dipeptides exhibit age-dependent toxicity in C. elegans.Human molecular genetics · 2017
   Article
5. Neurotrophic and Neuroregenerative Effects of GH/IGF1.International journal of molecular sciences · 2017
   Review
6. Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside.Frontiers in neuroscience · 2017
   Review
7. Impaired Mitophagy Plays a Role in Denervation of Neuromuscular Junctions in ALS Mice.Frontiers in neuroscience · 2017
   Article
8. IGF-1R Reduction Triggers Neuroprotective Signaling Pathways in Spinal Muscular Atrophy Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015
   Article
9. The therapeutic potential of IGF-I in skeletal muscle repair.Trends in endocrinology and metabolism: TEM · 2013
   Review
10. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
    Article
11. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?Frontiers in neuroscience · 2010
    Article

Corrections and comments

• Comment on
  Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.2008

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as